These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 9864172)

  • 1. BCR/ABL- CD34(+)HLA-DR- progenitor cells in early chronic phase, but not in more advanced phases, of chronic myelogenous leukemia are polyclonal.
    Delforge M; Boogaerts MA; McGlave PB; Verfaillie CM
    Blood; 1999 Jan; 93(1):284-92. PubMed ID: 9864172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients.
    Verfaillie CM; Bhatia R; Miller W; Mortari F; Roy V; Burger S; McCullough J; Stieglbauer K; Dewald G; Heimfeld S; Miller JS; McGlave PB
    Blood; 1996 Jun; 87(11):4770-9. PubMed ID: 8639848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of bcr/abl gene in single hemopoietic progenitors in some patients with chronic myelogenous leukemia.
    Misawa M; Maeda H; Hara H; Yamamoto Y; Furuyama J
    Stem Cells; 1993 Nov; 11(6):536-42. PubMed ID: 7509222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of autografting in chronic myelogenous leukemia: effects of priming regimen and marrow or blood origin of stem cells.
    Verfaillie CM; Bhatia R; Steinbuch M; DeFor T; Hirsch B; Miller JS; Weisdorf D; McGlave PB
    Blood; 1998 Sep; 92(5):1820-31. PubMed ID: 9716614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCR/ABL-negative progenitors are enriched in the adherent fraction of CD34+ cells circulating in the blood of chronic phase chronic myeloid leukemia patients.
    Grand FH; Marley SB; Chase A; Titley I; Healy L; Spencer A; Reiter A; Goldman JM; Gordon MY
    Leukemia; 1997 Sep; 11(9):1486-92. PubMed ID: 9305602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow.
    Leemhuis T; Leibowitz D; Cox G; Silver R; Srour EF; Tricot G; Hoffman R
    Blood; 1993 Feb; 81(3):801-7. PubMed ID: 7679000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression.
    Verfaillie CM; Miller WJ; Boylan K; McGlave PB
    Blood; 1992 Feb; 79(4):1003-10. PubMed ID: 1371077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia.
    Maguer-Satta V; Petzer AL; Eaves AC; Eaves CJ
    Blood; 1996 Sep; 88(5):1796-804. PubMed ID: 8781437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.
    Nakajima H; Zhao R; Lund TC; Ward J; Dolan M; Hirsch B; Miller JS
    J Immunol; 2002 Jan; 168(2):643-50. PubMed ID: 11777957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood is a source of BCR-ABL-negative pre-progenitors in early chronic phase chronic myeloid leukemia.
    Lewis ID; Haylock DN; Moore S; To LB; Hughes TP
    Leukemia; 1997 Apr; 11(4):581-7. PubMed ID: 9096699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benign marrow progenitors are enriched in the CD34+/HLA-DRlo population but not in the CD34+/CD38lo population in chronic myeloid leukemia: an analysis using interphase fluorescence in situ hybridization.
    Kirk JA; Reems JA; Roecklein BA; Van Devanter DR; Bryant EM; Radich J; Edmands S; Lee A; Torok-Storb B
    Blood; 1995 Jul; 86(2):737-43. PubMed ID: 7541674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferential sequestration in vitro of BCR/ABL negative hematopoietic progenitor cells among cytokine nonresponsive CML marrow CD34+ cells.
    Veena P; Cornetta K; Davidson A; Agüero B; McMahel J; Traycoff CM; Srour EF
    Bone Marrow Transplant; 1997 Jun; 19(12):1213-21. PubMed ID: 9208115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 30/35 kDa chymotryptic fragment of fibronectin enhances retroviral-mediated gene transfer in purified chronic myelogenous leukemia bone marrow progenitors.
    Traycoff CM; Srour EF; Dutt P; Fan Y; Cornetta K
    Leukemia; 1997 Jan; 11(1):159-67. PubMed ID: 9001433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
    Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
    Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
    Carlo-Stella C; Dotti G; Mangoni L; Regazzi E; Garau D; Bonati A; Almici C; Sammarelli G; Savoldo B; Rizzo MT; Rizzoli V
    Blood; 1996 Oct; 88(8):3091-100. PubMed ID: 8874208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idarubicin, intermediate-dose cytarabine, etoposide, and granulocyte-colony-stimulating factor are able to recruit CD34+/HLA-DR- cells during early hematopoietic recovery in accelerated and chronic phases of chronic myeloid leukemia.
    Carella AM; Frassoni F; Podestá M; Pungolino E; Pollicardo N; Ferrero R; Soracco M
    J Hematother; 1994; 3(3):199-202. PubMed ID: 7530135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic characterization of normal and CML CD34-positive cells: only the most primitive CML progenitors include Ph-neg cells.
    De Fabritiis P; Dowding C; Bungey J; Chase A; Angus G; Szydlo R; Goldman JM
    Leuk Lymphoma; 1993 Sep; 11(1-2):51-61. PubMed ID: 7693107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of IL-3 and G-CSF-mobilized peripheral blood stem cells in patients with early chronic phase CML.
    Heinzinger M; Waller CF; Rosenstiel A; Scheid S; Burger KJ; Lange W
    Leukemia; 1998 Mar; 12(3):333-9. PubMed ID: 9529127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A preliminary study on mechanisms for resistance of CML patient BM-derived bcr/abl+ and Flk1+CD31-CD34- stem cells to STI571 in vitro].
    Song YP; Fang BJ; Wei XD; Zheng S
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1004-9. PubMed ID: 16403268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic myelogenous leukemia: molecular and cellular aspects.
    Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
    J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.